ESO Lymphoma Course
Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib or Ibrutinib to R-CHOP? How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis?
By
ESO Lymphoma Course
FEATURING
Andrew Davies
By
ESO Lymphoma Course
FEATURING
Andrew Davies
Comments 0
Login to view comments.
Click here to Login
